infect
sarsassoci
coronaviru
sarscov
induc
atyp
pulmonari
diseas
high
lethal
rate
although
initi
sar
epidem
contain
sporad
outbreak
diseas
still
occur
suggest
continu
need
vaccin
viru
therefor
explor
exosomebas
vaccin
contain
spike
protein
sarscov
scontain
exosom
obtain
replac
transmembran
cytoplasm
domain
protein
vsvg
immunogen
efficaci
scontain
exosom
test
mice
compar
adenovir
vector
vaccin
express
protein
scontain
exosom
adenovir
vector
vaccin
induc
neutral
antibodi
titer
prime
sarss
exosom
vaccin
boost
adenovir
vector
neutral
antibodi
titer
exceed
observ
convalesc
serum
sar
patient
approach
effect
sarssexpress
tumor
challeng
model
thu
warrant
investig
first
report
sever
acut
respiratori
syndrom
sar
caus
newli
emerg
human
coronaviru
sarscov
drosten
et
al
drosten
et
al
diseas
character
atyp
sever
pulmonari
diseas
high
lethal
rate
chanyeung
chanyeung
yu
ho
et
al
within
month
first
outbreak
report
guangdong
provinc
china
sarscov
rapidli
spread
via
intern
travel
becam
seriou
problem
public
health
worldwid
date
sever
isol
sarscov
infect
still
occur
mainli
asia
although
major
outbreak
contain
sinc
indic
sarscov
infect
still
repres
threat
public
health
absenc
effect
therapi
sar
develop
effect
vaccin
still
need
sarscov
envelop
positivestrand
rna
viru
genom
nucleotid
encod
four
structur
protein
includ
spike
glycoprotein
nucleocapsid
protein
n
membran
protein
small
envelop
glycoprotein
e
sever
nonstructur
protein
like
coronavirus
unknown
function
marra
et
al
rota
et
al
spike
protein
bind
member
dcsign
famili
angiotensinconvert
enzym
jeffer
et
al
li
et
al
wang
et
al
therebi
mediat
entri
viru
target
cell
therefor
protein
repres
good
target
vaccin
develop
sarscov
exosom
releas
dendrit
cell
cancer
cell
propos
vaccin
candid
immunotherapi
tumor
andr
et
al
chaput
et
al
chaput
et
al
delcayr
et
al
taieb
et
al
zitvogel
et
al
small
membran
vesicl
diamet
nm
releas
via
multivesicular
bodi
varieti
differ
cell
type
proteom
profil
exosom
differ
substanti
cell
lysat
amigorena
mear
et
al
number
cellular
protein
tetraspanin
heat
shock
protein
mhci
molecul
enrich
vesicl
denzer
et
al
pech
et
al
admyr
et
al
hemler
andr
et
al
exosom
takenup
dendrit
cell
lead
present
mhcipeptid
complex
exosom
dendrit
cell
andr
et
al
cellular
compon
exosom
heat
shock
protein
report
enhanc
immunogen
efficaci
exosomebas
cancer
vaccin
chen
et
al
therefor
analyz
whether
exosom
vaccin
approach
could
also
exploit
develop
vaccin
envelop
virus
sar
coronaviru
incorpor
protein
sar
coronaviru
sarss
exosom
cytoplasm
transmembran
domain
sarss
replac
g
protein
vesicular
stomat
viru
chimer
protein
gtm
effici
express
cell
surfac
allow
entri
pseudotyp
retrovir
vector
incorpor
exosom
gtm
contain
exosom
test
immunogen
mous
model
novel
protein
vaccin
sarscov
given
immunostimulatori
properti
vsvg
marsac
et
al
kuat
et
al
also
explor
immunogen
exosom
gener
cell
coexpress
sarss
vsvg
protein
sarscov
type
transmembran
glycoprotein
compos
ectodomain
amino
acid
transmembran
domain
tm
amino
acid
cytoplasm
domain
cd
amino
acid
girogl
et
al
spiga
et
al
zeng
et
al
gener
express
plasmid
chimer
protein
code
region
transmembran
cytoplasm
domain
protein
replac
vsvg
gtm
schemat
represent
encod
recombin
polypeptid
shown
fig
order
assess
express
recombin
protein
cell
lysat
cell
transient
transfect
differ
sarscov
express
plasmid
analyz
western
blot
detect
protein
polyclon
antiserum
rais
amino
acid
subunit
use
shown
fig
wildtyp
well
recombin
protein
express
transfect
cell
precursor
polypeptid
molecular
weight
approxim
kda
could
detect
sampl
transfect
ps
wt
ps
gtm
antiserum
also
react
cellular
protein
approxim
molecular
weight
kda
fig
fusion
ectodomain
protein
nterminu
tm
vsvg
lead
express
hybrid
protein
membranebound
form
result
immunofluoresc
stain
fig
transfect
cell
sarsconvalesc
serum
inde
suggest
local
wt
gtm
confirm
cell
surfac
express
cell
transfect
express
plasmid
stain
sarsconvalesc
serum
without
disrupt
cellular
membran
shown
fig
wild
type
well
hybrid
protein
express
cell
surfac
mean
fluoresc
intens
cell
express
gtm
higher
compar
cell
express
wt
fig
compar
express
level
gtm
wt
surfac
cell
surfac
protein
transfect
cell
biotinyl
lyse
precipit
avidincoupl
bead
western
blot
analysi
precipit
reveal
effici
express
gtm
wt
surfac
cell
fig
right
panel
protein
could
detect
total
cell
lysat
fig
left
panel
result
indic
transmembran
cytoplasm
domain
vsvg
mediat
effici
transport
protein
ectodomain
cell
membran
homolog
domain
product
fulli
function
hybrid
protein
retain
much
conform
parent
protein
import
vaccin
design
sinc
neutral
antibodi
gener
immun
hybrid
protein
also
abl
neutral
wildtyp
sarscov
addit
could
benefici
receptor
induc
conform
chang
hybrid
protein
also
mimic
parent
protein
test
whether
gtm
protein
function
activ
siv
hiv
mlvbase
vector
pseudotyp
either
wildtyp
hybrid
protein
vector
titer
determin
cell
suscept
vector
transduct
cell
data
shown
infecti
siv
hiv
mlv
vector
obtain
use
hybrid
protein
gtm
titer
absenc
viral
surfac
protein
gfuml
incorpor
gtm
vector
particl
fig
seem
correl
titer
obtain
siv
mlv
vector
fig
similar
titer
obtain
three
vector
pseudotyp
vsvg
vector
titer
gtm
pseudotyp
higher
obtain
pseudotyp
wt
although
latter
could
hardli
detect
particl
prepar
high
effici
express
gtm
surfac
cell
may
also
lead
increas
incorpor
exosom
releas
transfect
cell
order
assess
western
blot
analys
perform
pellet
vesicl
ps
wtand
ps
gtm
transfect
cell
use
antibodi
shown
fig
protein
could
detect
sampl
ps
wt
transfect
cell
contrast
gtm
protein
could
detect
pellet
supernat
ps
gtm
transfect
cell
also
check
presenc
protein
characterist
exosom
includ
heat
shock
protein
tetraspanin
protein
western
blot
analysi
vesicl
deriv
cell
transfect
ps
gtm
reveal
presenc
protein
molecular
weight
kda
kda
respect
fig
addit
expect
protein
western
blot
analysi
antibodi
reveal
incorpor
unknown
protein
molecular
weight
kda
contrast
relat
protein
detect
blot
sampl
ps
wt
mocktransfect
cell
fig
presenc
protein
correl
incorpor
gtm
pellet
vesicl
indic
gtm
wildtyp
protein
wt
may
enhanc
releas
exosom
condit
media
order
check
gtm
membran
bound
gtm
pellet
supernat
transfect
cell
sucros
cushion
resuspend
incub
og
mild
deterg
solubil
lipid
membran
ogtreat
sampl
layer
sucros
cushion
follow
ultracentrifug
western
blot
analysi
pellet
concentr
supernat
fig
og
treatment
gtm
almost
exclus
found
supernat
absenc
gtm
pellet
due
loss
gtm
whole
procedur
sinc
gtm
could
cell
transfect
transient
indic
express
plasmid
incub
convalesc
serum
sar
patient
bound
antibodi
detect
use
fitcconjug
antihuman
secondari
antibodi
upper
panel
repres
magnif
imag
lower
panel
magnif
b
fac
analysi
cell
transient
transfect
plasmid
encod
wildtyp
protein
wt
hybrid
protein
gtm
fac
analysi
perform
intact
cell
use
sar
patient
serum
fitcconjug
anti
human
igg
level
protein
express
express
mean
fluoresc
intens
mfi
neg
control
mocktransfect
cell
use
c
biotinyl
assay
cell
transfect
express
plasmid
indic
protein
half
transfect
cell
lyse
directli
extracellular
domain
membran
protein
half
first
biotinyl
precipit
avidin
bead
lysat
transfect
cell
cell
lysat
biotinyl
precipit
surfac
protein
cell
surfac
analyz
western
blot
antiserum
number
lefthand
side
figur
indic
posit
molecular
weight
size
marker
repellet
absenc
og
fig
thu
gtm
seem
incorpor
membran
vesicl
releas
transfect
cell
resembl
exosom
structur
test
immunogen
sarsscontain
exosom
cell
transient
transfect
gtm
express
plasmid
serumfre
condit
media
harvest
exosom
partial
purifi
ultracentrifug
sucros
cushion
sinc
previous
observ
incorpor
vsvg
immunodefici
viruslik
particl
enhanc
immun
respons
gag
kuat
et
al
also
coexpress
vsvg
gtm
cell
purifi
releas
exosom
ultracentrifug
exosom
prepar
contain
similar
amount
gtm
fig
left
panel
prepar
exosom
cell
coexpress
vsvg
sarss
g
gtm
contain
protein
fig
right
panel
western
blot
analysi
protein
detect
use
antibodi
recogn
cytoplasm
domain
vsvg
ratio
band
intens
gtm
vsvg
protein
therefor
indic
vaccin
prepar
vsvg
present
molar
excess
fig
right
panel
exosomebas
vaccin
compar
adenovir
vector
express
gtm
sinc
adenovir
vector
vaccin
shown
induc
strong
immun
respons
broad
spectrum
antigen
encod
adenovir
vector
adenovir
gtm
vector
construct
use
modifi
padeasi
system
et
al
kuat
et
al
adenovir
vector
purifi
cscl
gradient
centrifug
express
gtm
confirm
western
blot
analysi
data
shown
also
explor
primeboost
regimen
prime
exosom
vaccin
boost
adenovir
vector
vaccin
singl
inject
adenovir
vector
express
gtm
induc
antibodi
bind
sarss
express
murin
cell
fig
exosom
vaccin
two
inject
requir
induc
similar
antibodi
level
sarss
fig
coexpress
vsvg
sarss
g
gtm
led
slight
increas
antibodi
level
sarss
highest
antibodi
level
obtain
prime
gtm
exosom
boost
adenovir
vector
vaccin
fig
right
panel
although
bind
antibodi
level
significantli
higher
vaccin
group
compar
nonvaccin
control
group
p
oneway
anova
logtransform
mfi
differ
vaccin
group
reach
statist
signific
determin
neutral
antibodi
titer
spseudotyp
retrovir
vectorbas
fig
b
wildtyp
sarscovbas
fig
neutral
assay
perform
use
spseudotyp
neutral
assay
highest
serum
dilut
reduc
vector
infect
determin
order
avoid
minor
unspecif
inhibitori
effect
sera
high
concentr
highest
neutral
antibodi
titer
obtain
anim
prime
gtm
boost
ad
gtm
vector
fig
comparison
neutral
antibodi
titer
group
group
immun
ad
gtm
indic
gtm
immun
prime
effect
fig
two
inject
exosom
gtm
vaccin
also
induc
substanti
neutral
antibodi
titer
slightli
higher
vsvg
includ
exosom
vaccin
fig
neutral
antibodi
specif
inhibit
sarssmedi
entri
sinc
sera
reduc
titer
retrovir
vector
contain
amphotrop
mlvenv
instead
sarss
fig
compar
neutral
activ
antibodi
obtain
immun
mice
obtain
natur
sar
coronaviru
infect
human
convalesc
serum
sar
patient
obtain
week
onset
symptom
analyz
side
side
select
mous
sera
use
pseudotyp
retrovir
vector
sera
gtm
ad
gtmimmun
mice
inhibit
vector
infect
effici
convalesc
serum
sar
patient
fig
confirm
antibodi
inhibit
entri
sarsspseudotyp
retrovir
vector
also
neutral
wildtyp
sarscov
pool
antisera
group
mice
receiv
two
gtm
inject
gtm
prime
adenovir
vector
boost
immun
test
viru
neutral
assay
consist
highest
neutral
activ
obtain
gtm
prime
adenovir
vector
boost
regimen
induc
higher
titer
neutral
antibodi
detect
convalesc
serum
sar
patient
fig
tumor
challeng
model
establish
explor
rel
efficaci
differ
sarssbas
vaccin
end
melanoma
cell
establish
stabli
express
wildtyp
sarss
protein
nonimmun
mice
inocul
cell
develop
tumor
within
week
inject
fig
immun
mice
challeng
tumor
cell
week
singl
immun
week
booster
immun
singl
immun
rate
tumor
growth
slightli
delay
vaccin
anim
compar
control
fig
delay
pronounc
ad
gtm
immun
anim
compar
rate
tumor
growth
differ
vaccin
group
oneway
anova
test
perform
logtransform
tumor
volum
day
challeng
time
point
tumor
volum
control
anim
alreadi
reach
mm
fig
larger
tumor
volum
observ
control
anim
compar
obtain
vaccin
group
howev
statist
signific
differ
tumor
growth
found
control
group
ad
gtm
immun
anim
p
primeboost
immun
regimen
pattern
tumor
growth
control
mice
singl
immun
regimen
observ
vaccine
rate
tumor
pellet
gtm
resuspend
treat
og
repellet
sucros
cushion
ultracentrifug
centrifug
pellet
harvest
supernat
sup
concentr
ultrafiltr
sampl
obtain
pellet
sup
analyz
presenc
protein
western
blot
use
antiserum
control
untreat
pellet
gtm
pellet
condit
media
mocktransfect
cell
neg
process
way
c
western
blot
analysi
exosom
vaccin
condit
media
cell
transfect
plasmid
express
hybrid
protein
togeth
g
gtm
gtm
express
vsvg
concentr
ultracentrifug
exosom
analyz
western
blot
use
antiserum
left
panel
antivsvg
antibodi
right
panel
fig
bind
antibodi
level
cell
stabli
express
protein
incub
sera
obtain
singl
immun
indic
primeboost
regimen
b
wash
remov
unbound
antibodi
cell
incub
fitclabel
antimous
antibodi
fac
analysi
perform
determin
mean
fluoresc
intens
sampl
growth
strongli
retard
compar
control
anim
fig
singl
immun
anim
receiv
ad
gtm
booster
immun
group
gtm
ad
gtm
control
effici
tumor
growth
control
tumor
growth
sarss
specif
mice
immun
twice
gtm
control
growth
cell
express
protein
data
shown
comparison
tumor
volum
day
post
challeng
show
statist
signific
differ
vaccin
group
fig
howev
statist
signific
differ
found
compar
volum
tumor
control
anim
immun
gtm
p
g
gtm
p
gtm
ad
gtm
p
exchang
transmembran
domain
cytoplasm
domain
sarscov
correspond
domain
vsvg
alter
cellular
fate
protein
substanti
cytoplasm
domain
vsvg
previous
shown
determin
transport
pathway
hart
et
al
andersson
et
al
basolater
local
vsvg
polar
cell
mcqueen
et
al
brown
et
al
compton
et
al
fuse
heterolog
protein
fig
neutral
assay
sera
mice
immun
indic
vaccin
dilut
serial
serumfre
dmem
medium
incub
spseudotyp
mlv
vector
cocktail
ad
triplic
cell
transient
express
receptor
two
day
later
gfpposit
cell
count
fluoresc
microscop
highest
dilut
led
inhibit
vector
infect
compar
control
infect
taken
neutral
antibodi
titer
close
symbol
log
titer
given
control
infect
specif
neutral
antibodi
perform
use
mlvbase
vector
contain
amphotrop
mlv
env
open
symbol
b
comparison
neutral
activ
antisera
immun
mice
convalesc
sar
patient
inhibit
spseudotyp
mlv
vector
incub
differ
dilut
control
serum
cserum
serum
sarsrecov
patient
pserum
sera
mice
immun
indic
determin
log
serum
dilut
given
xaxi
c
viru
neutral
assay
vero
cell
infect
triplic
wildtyp
sarscov
incub
differ
dilut
antisera
indic
experiment
anim
group
monitor
day
latter
format
cytopath
effect
neutral
antibodi
titer
present
highest
dilut
antisera
prevent
cytopath
effect
well
membran
span
cytoplasm
domain
vsvg
target
heterolog
protein
cell
surfac
allow
effici
incorpor
viral
vector
particl
owen
rose
jin
wright
also
observ
ectodomain
sarscov
gtm
fusion
protein
express
higher
level
cell
surfac
compar
wildtyp
protein
comparison
gtm
incorpor
wildtyp
viral
particl
sever
reduc
gtm
incorpor
viral
particl
also
function
activ
allow
transduct
cell
pseudotyp
retrovir
lentivir
vector
indic
sarssmedi
fusion
viral
membran
cellular
membran
disturb
heterolog
transmembran
cytoplasm
domain
suggest
neutral
epitop
sarss
maintain
gtm
transfect
cell
express
plasmid
gtm
also
led
secret
gtm
consist
exosom
local
secret
gtm
seem
membran
bound
could
pellet
sucros
cushion
western
blot
analysi
gtm
wt
vesicl
vesicl
mocktransfect
cell
reveal
presenc
two
sever
protein
characterist
exosom
wubbolt
et
al
clayton
et
al
although
exosom
constitut
secret
sever
cell
type
consequ
fusion
multivesicular
bodi
plasma
membran
lack
detect
protein
wt
mockderiv
vesicl
suggest
gtm
either
induc
exosom
format
enhanc
incorpor
exosom
remain
determin
whether
function
map
transmembran
like
cytoplasm
domain
vsvg
contrast
solubl
protein
vaccin
exosom
contain
membraneanchor
ectodomain
viral
surfac
protein
multipl
copi
viral
protein
expos
surfac
exosom
therebi
facilit
crosslink
b
cell
receptor
respect
mirror
virosom
vaccin
made
reconstitut
purifi
viral
membran
protein
liposom
differ
virosom
vaccin
fact
exosom
contain
viral
protein
also
wide
array
cellular
protein
shown
support
induct
immun
respons
although
exosom
vaccin
primarili
rais
interest
due
fact
allow
cross
present
lead
induct
cell
respons
multimer
present
viral
surfac
protein
natur
confirm
might
also
effici
trigger
viral
surfac
proteinspecif
b
cell
receptor
particularli
cellular
compon
exosom
provid
addit
stimulatori
signal
sinc
could
also
favor
induct
neutral
antibodi
explor
potenti
gtmcontain
exosom
novel
vaccin
approach
sar
coronaviru
infect
two
inject
gtmcontain
xenogen
exosom
without
adjuv
suffici
induc
neutral
antibodi
titer
prime
sarss
exosom
vaccin
boost
adenovir
vector
neutral
antibodi
titer
exceed
sarsconvalesc
patient
serum
fig
previou
immun
studi
use
solubl
protein
sever
immun
presenc
adjuv
necessari
gener
reason
neutral
antibodi
titer
keng
et
al
previous
observ
incorpor
fusioncompet
fusiondefici
vsvg
vlp
led
approxim
increas
antibodi
titer
capsid
protein
kuat
et
al
indic
fusion
activ
vsvg
requir
immunostimulatori
properti
suggest
vsvgmediat
shuttl
vlpassoci
antigen
particular
cellular
compart
dramat
enhanc
humor
immun
respons
howev
incorpor
vsvg
gtm
contain
exosom
lead
signific
increas
bind
neutral
antibodi
sarss
sinc
gtm
fusioncompet
enhanc
effect
fusioncompet
vsvg
might
mask
altern
immunostimulatori
properti
vsvg
might
differ
depend
type
coadminist
antigen
fusion
exosom
membran
endosom
membran
larg
ectodomain
membran
anchor
gtm
lumen
endosom
capsid
protein
local
within
vlp
reach
cytoplasm
although
vsvg
gtm
contain
cytoplasm
domain
direct
intracellular
traffick
formal
exclud
possibl
vsvg
gtm
local
differ
exosom
might
also
explain
poor
enhanc
effect
vsvg
sarss
antibodi
titer
sinc
gtm
contain
exosom
prepar
human
cell
expect
contain
number
human
protein
might
target
murin
immun
respons
therefor
also
determin
immunogen
adenovir
vector
express
gtm
inject
adenovir
vector
mice
lead
express
gtm
vaccine
subsequ
releas
exosom
contain
gtm
heterolog
protein
singl
inject
gtm
express
adenovir
vector
induc
neutral
antibodi
reduc
growth
sarssexpress
tumor
cell
confirm
immunogen
adenovir
vector
vaccin
whether
releas
gtmcontain
exosom
vivo
contribut
strong
immun
respons
observ
remain
determin
immun
respons
adenovir
vector
particl
limit
repeat
applic
adenovir
vector
vaccin
bangari
mittal
barouch
et
al
yang
et
al
therefor
use
primeboost
regimen
consist
gtm
contain
exosom
follow
adenovir
vector
boost
primeboost
regimen
induc
highest
neutral
antibodi
titer
exceed
titer
obtain
singl
adenovir
vector
immun
two
dose
gtm
contain
exosom
neutral
antibodi
titer
induc
immun
parallel
effici
control
growth
sarssexpress
tumor
cell
mice
receiv
heterolog
homolog
primeboost
regimen
abl
inhibit
tumor
growth
singl
inject
gtm
express
adenovir
vector
inhibit
tumor
growth
similar
extent
primeboost
regimen
howev
transient
suppress
tumor
growth
observ
growth
pattern
previous
describ
ovalbuminimmun
mice
challeng
cell
stabli
express
ovalbumin
bonifaz
et
al
select
tumor
cell
express
sarss
subsequ
outgrowth
might
explain
observ
chosen
tumor
challeng
model
avoid
work
infecti
sar
coronaviru
although
know
present
whether
model
predict
vaccin
efficaci
sar
coronaviru
infect
anim
model
human
repres
addit
paramet
allow
preclin
rank
differ
vaccin
approach
evalu
sinc
gtm
contain
exosom
gtm
express
adenovir
vector
induc
neutral
antibodi
titer
exceed
observ
convalesc
serum
sar
patient
combin
primeboost
regimen
sinc
humor
immun
alon
could
control
coronaviru
replic
murin
model
approach
warrant
investig
human
embryon
kidney
cell
deriv
dubridg
et
al
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
karlsruh
germani
supplement
fetal
calf
serum
fc
lglutamin
penicillin
streptomycin
vero
cell
maintain
minim
essenti
medium
mem
invitrogen
karlsruh
germani
supplement
fc
plasmid
purchas
clontech
heidelberg
germani
construct
plasmid
schnell
et
al
hgpsyn
wagner
et
al
phitg
fouchier
et
al
hivclcg
miyoshi
et
al
pctatrev
southgat
et
al
pcagg
pcdnaacez
hofmann
pohlmann
describ
construct
express
plasmid
chimer
protein
transmembran
cytoplasm
domain
chappl
jone
codonoptim
version
g
protein
vesicular
stomat
viru
amplifi
plasmid
pcdgsyn
unpublish
data
use
primer
acaagctgctagccagccatagagcccaccgcatccccagcat
flank
restrict
enzym
swai
nhei
respect
pcr
product
digest
swai
nhei
insert
frame
swainhei
digest
ps
wt
pcagg
hofmann
et
al
gener
ps
gtm
cell
plate
cm
flask
transfect
day
later
ps
wt
ps
gtm
togeth
gfpexpress
plasmid
order
monitor
transfect
effici
two
day
later
transfect
cell
resuspend
protein
load
buffer
sampl
denatur
min
fifteen
microlit
sampl
thereaft
separ
use
sdspage
protein
transfer
onto
nitrocellulos
membran
schleicher
schuell
bioscienc
dassel
germani
use
standard
techniqu
blot
subsequ
incub
dilut
rabbit
antiserum
rais
biomol
gmbh
hamburg
germani
dilut
goat
antirabbit
antiserum
conjug
horseradish
peroxidas
sigma
taufkirchen
germani
wash
protein
band
detect
use
commerci
avail
chemiluminesc
western
blot
detect
kit
biozym
scientif
gmbh
oldendorf
germani
accord
manufactur
instruct
cell
plate
cm
flask
transfect
day
later
ps
wt
ps
gtm
carrier
dna
two
day
later
cell
detach
flask
use
mm
edta
pb
wash
two
time
pb
transfer
onto
slide
centrifug
use
cytospin
centrifug
shandon
biomed
polym
inc
gardner
usa
cell
thereaft
fix
min
cold
aceton
incub
h
dilut
serum
obtain
sar
patient
week
hospit
wash
elimin
unbound
antibodi
cell
incub
min
fitcconjug
antihuman
igg
dakocytom
gmbh
hamburg
germani
dilut
evan
blue
solut
anoth
wash
step
presenc
green
cell
monitor
fluoresc
microscop
pictur
taken
cell
plate
transfect
describ
ps
wt
ps
gtm
two
day
transfect
cell
detach
flask
describ
immunofluoresc
assay
wash
three
time
fac
buffer
fc
pb
cellswel
transfer
vbottom
microtit
plate
incub
min
patient
serum
dilut
fac
buffer
three
wash
fac
buffer
cell
incub
min
dark
fitcconjug
antihuman
igg
dilut
fac
buffer
contain
propidium
iodid
wash
cell
analyz
use
fac
calibur
becton
dickinson
heidelberg
germani
biotinyl
assay
cell
transfect
plasmid
express
wildtyp
protein
mutant
two
day
later
half
cell
lyse
load
buffer
use
sdspage
half
use
biotinyl
surfac
protein
essenti
previous
describ
sandrin
et
al
produc
spseudotyp
vector
cell
plate
cm
flask
densiti
cellsflask
transfect
day
later
vector
plasmid
hivclcg
packag
plasmid
hgpsyn
respect
envelop
express
plasmid
ps
wt
ps
gtm
phitg
describ
product
hivbas
vector
plasmid
pctatrev
also
cotransfect
eight
hour
transfect
condit
media
discard
cell
fed
ml
fresh
serumfre
medium
aimv
invitrogen
karlsruh
germani
one
day
later
condit
media
harvest
clear
cell
debri
low
speed
centrifug
pass
filter
determin
vector
titer
cell
transient
transfect
plasmid
express
plate
plate
densiti
cellswel
infect
day
later
serial
dilut
condit
media
two
day
later
gfpposit
cell
count
fluoresc
microscop
vector
titer
calcul
number
gfpposit
cell
well
cell
plate
cm
tissu
cultur
flask
densiti
cellsflask
transfect
day
later
either
wt
gtm
express
plasmid
two
day
transfect
condit
media
harvest
vesicl
contain
media
pellet
ultracentrifug
sucros
cushion
western
blot
analysi
use
antibodi
perform
directli
compar
incorpor
wildtyp
wt
hybrid
gtm
protein
vesicl
pellet
vesicl
also
subject
western
blot
analysi
describ
use
dilut
mous
monoclon
antibodi
direct
santa
cruz
biotechnolog
heidelberg
germani
respect
prepar
exosom
vaccin
cell
plate
describ
transfect
day
later
plasmid
express
gtm
togeth
plasmid
express
g
protein
vsvg
eight
hour
transfect
cell
fed
ml
fresh
serumfre
medium
aimv
invitrogen
karlsruh
germani
one
day
later
condit
media
harvest
exosom
concentr
ultracentrifug
describ
pellet
resuspend
pb
use
western
blot
analysi
kept
experi
order
assess
membranebound
natur
gtm
resuspend
pellet
obtain
supernat
transfect
cell
ultracentrifug
sucros
cushion
incub
h
mm
og
applichem
darmstadt
germani
gentl
shack
order
solubil
cell
membran
treat
untreat
use
control
sampl
repellet
sucros
contain
mm
og
describ
assess
solubil
protein
supernat
ogtreat
sampl
collect
centrifug
concentr
approxim
use
vivaspin
ultrafiltr
spin
column
cutoff
molecular
weight
vivaspin
ag
goetingen
germani
describ
manufactur
presenc
protein
differ
sampl
prepar
assess
western
blot
analysi
experi
condit
media
mocktransfect
cell
concentr
ultracentrifug
use
neg
control
anim
experi
total
protein
exosom
vaccin
use
per
inocul
similar
amount
protein
observ
western
blot
analysi
differ
vaccin
prepar
product
recombin
adenovir
vector
express
hybrid
gtm
protein
gtm
gene
subclon
ps
gtm
plasmid
plasmid
gener
gtm
homolog
recombin
bacteria
cell
cotransform
electropor
linear
gtm
recombin
plasmid
et
al
result
recombin
plasmid
digest
paci
transfect
trex
cell
viral
product
adenovir
particl
amplifi
cell
purifi
standard
cesiumchlorid
gradient
centrifug
previous
describ
particl
concentr
vector
particl
determin
optic
densiti
measur
previous
describ
mittered
et
al
immun
five
group
mice
charl
river
wiga
gmbh
sulzfeld
germani
inject
footpad
total
protein
exosom
vaccin
singl
immun
anim
n
receiv
either
gtm
group
gtm
gtm
vsvg
group
g
gtm
particl
recombin
adenovir
vector
express
gtm
group
ad
gtm
two
week
later
blood
sampl
collect
retroorbit
anim
challeng
inject
right
flank
melanoma
cell
stabli
express
wildtyp
protein
neg
control
six
mice
also
challeng
cell
primeboost
experi
anim
n
either
receiv
two
inject
gtm
group
gtm
two
inject
gtm
vsvg
group
g
gtm
week
one
group
gtm
ad
gtm
prime
gtm
week
boost
week
later
ad
gtm
one
week
last
immun
blood
sampl
collect
anim
challeng
cell
describ
tumor
growth
monitor
daili
volum
tumor
determin
everi
day
anim
sacrif
tumor
volum
exceed
mm
assess
specif
tumor
suppress
mice
n
immun
week
gtm
vaccin
challeng
week
cell
express
protein
analysi
bind
antibodi
cell
plate
densiti
cellswel
ubottom
plate
incub
min
dilut
sera
collect
immun
control
anim
cell
thereaft
wash
twice
fac
buffer
incub
min
room
temperatur
dilut
fitclabel
monoclon
antibodi
mous
immunoglobulin
dakocytom
gmbh
hamburg
germani
anoth
seri
wash
cell
analyz
flow
cytometri
describ
amount
antibodi
express
mean
fluoresc
intens
determin
neutral
antibodi
titer
spseudotyp
mlv
vector
produc
describ
infect
cell
transient
express
protein
plate
plate
densiti
cellswel
one
day
later
differ
dilut
sera
incub
min
vector
particl
mixtur
ad
triplic
cell
two
day
infect
gfpexpress
cell
count
fluoresc
microscop
neutral
titer
determin
highest
serum
dilut
inhibit
infect
order
check
specif
neutral
assay
assay
perform
use
mlv
vector
contain
amphotrop
mlvenv
compar
neutral
properti
antisera
immun
mice
sarsrecov
patient
two
antisera
chosen
experi
one
lowest
neutral
antibodi
titer
gtm
group
anoth
one
highest
titer
gtm
ad
gtm
group
antisera
togeth
sarsrecov
patient
serial
dilut
incub
spseudotyp
mlv
vector
subsequ
cell
express
receptor
infect
sampl
two
day
later
number
gfpposit
cell
use
calcul
percentag
vector
infect
control
human
antiserum
use
assess
specif
inhibit
addit
neutral
assay
perform
use
wildtyp
sarscov
frankfurt
strain
antisera
group
immun
anim
primeboost
regimen
pool
serial
dilut
antisera
incub
h
tcid
well
sarscov
mixtur
ad
triplic
fresh
vero
cell
neg
control
fresh
media
instead
viru
antisera
mixtur
ad
cell
day
incub
cell
monitor
microscop
cpe
format
neutral
antibodi
titer
given
invers
serum
dilut
prevent
cytopath
effect
well
antiserum
convalesc
sar
patient
differ
patient
frankfurt
sar
strain
isol
also
includ
assay
direct
comparison
neutral
properti
antisera
immun
mice
statist
analysi
softwar
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
use
oneway
anova
analysi
perform
logtransform
data
post
test
perform
overal
p
less
post
test
bonferroni
multipl
comparison
test
perform
compar
neutral
antibodi
titer
group
nonparametr
mannwhitney
test
perform
